299 related articles for article (PubMed ID: 23653047)
21. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
22. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
23. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
24. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.
Hafner V; Albermann N; Haefeli WE; Ebinger F
Antimicrob Agents Chemother; 2008 Nov; 52(11):4172-4. PubMed ID: 18794387
[TBL] [Abstract][Full Text] [Related]
26. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole pharmacokinetics and pharmacodynamics in children.
Neely M; Rushing T; Kovacs A; Jelliffe R; Hoffman J
Clin Infect Dis; 2010 Jan; 50(1):27-36. PubMed ID: 19951112
[TBL] [Abstract][Full Text] [Related]
28. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
30. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
31. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
32. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.
Hohmann N; Kreuter R; Blank A; Weiss J; Burhenne J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2017 Sep; 83(9):1954-1965. PubMed ID: 28370390
[TBL] [Abstract][Full Text] [Related]
33. Effect of grapefruit juice on serum voriconazole concentrations in the mouse.
Sugar AM; Liu XP
Med Mycol; 2000 Jun; 38(3):209-12. PubMed ID: 10892988
[TBL] [Abstract][Full Text] [Related]
34. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
35. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.
Hohmann N; Kocheise F; Carls A; Burhenne J; Weiss J; Haefeli WE; Mikus G
Clin Pharmacokinet; 2016 Dec; 55(12):1535-1545. PubMed ID: 27236320
[TBL] [Abstract][Full Text] [Related]
36. Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax.
Dong J; Liu SB; Rasheduzzaman JM; Huang CR; Miao LY
Pharm Res; 2022 Aug; 39(8):1921-1933. PubMed ID: 35725843
[TBL] [Abstract][Full Text] [Related]
37. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
38. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
[TBL] [Abstract][Full Text] [Related]
39. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
40. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
